Aptamers for Cardiovascular Diseases Diagnosis

With many advantages over other therapeutic agents such as monoclonal antibodies (mAbs), aptamers have recently emerged as a novel and powerful class of ligands with excellent potential for diagnostic applications. At Creative Biolabs, aptamers could be selected against various molecular targets involved in cardiovascular diseases (CVDs). With continued efforts in the development of aptamer-based diagnostics, Creative Biolabs has found its niches in CVD research. We provide a comprehensive set of aptamer generation as well as modification services against biomarkers involved in CVD for worldwide customers.

Cardiovascular Diseases and Biomarkers

In theory, aptamers can be selected for developing diagnostic tools for various diseases as long as definite targets are available. To date, DNA/RNA aptamers have been explored mainly for the diagnosis of infectious diseases, cancer, and CVDs. In the case of CVD, markers in the blood such as low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), myoglobin, I-homocysteine, and thrombin have been widely used to select DNA aptamer for the diagnosis of related diseases.

• Myoglobin increases after acute myocardial infarction. It is an important early marker in the urgent diagnosis of CVDs. Scientists selected DNA aptamers against myoglobin using a reported fluidic chip method. The DNA aptamer with the lowest Kd value (4.93 nM) was subjected to the development of different biosensors for the detection of myoglobin.
• CRP is a homopentameric oligoprotein. Many DNA aptamers targeting CRP have been screened and some are used to develop sensors based on surface plasmon resonance (SPR) technology.
• DNA aptamers targeting l-homocysteine have been developed as an aptamer-AuNP sensor, in which the DNA aptamers first coil around the surface of the gold particles and release the particles after binding to the homocysteine.
• von Willebrand factor (vWF)
• Thrombin
• Factor IX
• …….

Services at Creative Biolabs

Creative Biolabs proposes a novel methodology to synthesize high-density DNA/RNA aptamers arrays. Identified aptamers for the cardiac biomarkers will be tested for their limit of detection in human serum. To expand the universality of the assay beyond the limitations of antibodies currently used in different assays, a fluorescent protein dye could be optionally used to correlate array fluorescence intensity to biomarker concentration. A panel of aptamers has been also developed to detect specific glycosylated forms of cardiac biomarkers. Direct binding-based mode, target-induced structural switching mode, sandwich-like mode, and target-induced dissociation mode are available for sensor development. Constructs could be further evaluated in in vivo study. Detailed services include but not limited to the following:

• Anti-CVD biomarker DNA/RNA aptamers development
• Aptamer or its derivatives in vivo evaluation services
• Aptamer-based therapeutic applications assessment
• Aptamer conjugation services

Features

• Aptamer-based proteomic profiling
• Different diagnostic models
• Various CVD biomarker candidates

If you are interested in aptamer development for CVD detection, please feel free to contact us for more information or a detailed quotation.

For Research Use Only.